These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23146028)

  • 1. PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome.
    Estevez-Garcia P; Castaño A; Martin AC; Lopez-Rios F; Iglesias J; Muñoz-Galván S; Lopez-Calderero I; Molina-Pinelo S; Pastor MD; Carnero A; Paz-Ares L; Garcia-Carbonero R
    BMC Cancer; 2012 Nov; 12():514. PubMed ID: 23146028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-derived growth factor (PDGF) cross-signaling via non-corresponding receptors indicates bypassed signaling in colorectal cancer.
    Moench R; Gasser M; Nawalaniec K; Grimmig T; Ajay AK; de Souza LCR; Cao M; Luo Y; Hoegger P; Ribas CM; Ribas-Filho JM; Malafaia O; Lissner R; Hsiao LL; Waaga-Gasser AM
    Oncotarget; 2022 Oct; 13():1140-1152. PubMed ID: 36264073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy.
    Berardi R; Brunelli A; Pagliaretta S; Paolucci V; Conti A; Goteri G; Refai M; Pompili C; Marcantognini G; Morgese F; Ballatore Z; Savini A; De Lisa M; Caramanti M; Santoni M; Zizzi A; Piva F; Mazzanti P; Onofri A; Sabbatini A; Scarpelli M; Cascinu S
    Oncotarget; 2015 Aug; 6(22):19305-15. PubMed ID: 26254278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategy.
    Wehler TC; Frerichs K; Graf C; Drescher D; Schimanski K; Biesterfeld S; Berger MR; Kanzler S; Junginger T; Galle PR; Moehler M; Gockel I; Schimanski CC
    Oncol Rep; 2008 Mar; 19(3):697-704. PubMed ID: 18288404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression.
    Carvalho I; Milanezi F; Martins A; Reis RM; Schmitt F
    Breast Cancer Res; 2005; 7(5):R788-95. PubMed ID: 16168125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression and clinical significance of PDGFRalpha and PDGFRbeta in colorectal cancer].
    Zhu HT; Han J; Ma L
    Ai Zheng; 2008 Jun; 27(6):654-60. PubMed ID: 18570744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
    Burger H; den Bakker MA; Kros JM; van Tol H; de Bruin AM; Oosterhuis W; van den Ingh HF; van der Harst E; de Schipper HP; Wiemer EA; Nooter K
    Cancer Biol Ther; 2005 Nov; 4(11):1270-4. PubMed ID: 16294026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations.
    Liegl B; Gülly C; Reich O; Nogales FF; Beham A; Regauer S
    Histopathology; 2007 Mar; 50(4):448-52. PubMed ID: 17448020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of the PDGFR family together with SRC leads to diminished proliferation of colorectal cancer cells.
    Kaulfuß S; Seemann H; Kampe R; Meyer J; Dressel R; König B; Scharf JG; Burfeind P
    Oncotarget; 2013 Jul; 4(7):1037-49. PubMed ID: 23900414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.
    Wilczynski SP; Chen YY; Chen W; Howell SB; Shively JE; Alberts DS
    Hum Pathol; 2005 Mar; 36(3):242-9. PubMed ID: 15791568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulated PDGFR alpha expression and novel somatic mutations in colorectal cancer: association to RAS wild type status and tumor size.
    Ben Jemii N; Tounsi-Kettiti H; Yaiche H; Mezghanni N; Jaballah Gabteni A; Fehri E; Ben Fayala C; Abdelhak S; Boubaker S
    J Transl Med; 2020 Nov; 18(1):440. PubMed ID: 33213472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFRalpha in colorectal cancer.
    Schimanski CC; Zimmermann T; Schmidtmann I; Gockel I; Lang H; Galle PR; Moehler M; Berger MR
    Int J Colorectal Dis; 2010 Feb; 25(2):181-6. PubMed ID: 19936766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular analysis of PDGFRalpha/beta genes in core binding factor leukemia with eosinophilia.
    Monma F; Nishii K; Lorenzo F; Usui E; Ueda Y; Watanabe Y; Kawakami K; Oka K; Mitani H; Sekine T; Tamaki S; Mizutani M; Yagasaki F; Doki N; Miyawaki S; Katayama N; Shiku H
    Eur J Haematol; 2006 Jan; 76(1):18-22. PubMed ID: 16343267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenesis and angiogenic tyrosine kinase receptor expression in pediatric brain tumors.
    Virág J; Kenessey I; Haberler C; Piurkó V; Bálint K; Döme B; Tímár J; Garami M; Hegedűs B
    Pathol Oncol Res; 2014 Apr; 20(2):417-26. PubMed ID: 24190638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
    Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
    J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence.
    Jansson S; Aaltonen K; Bendahl PO; Falck AK; Karlsson M; Pietras K; Rydén L
    Breast Cancer Res Treat; 2018 Jun; 169(2):231-241. PubMed ID: 29380207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet‑derived growth factor receptor‑β gene expression relates to recurrence in colorectal cancer.
    Fujino S; Miyoshi N; Ohue M; Takahashi Y; Yasui M; Hata T; Matsuda C; Mizushima T; Doki Y; Mori M
    Oncol Rep; 2018 May; 39(5):2178-2184. PubMed ID: 29498405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
    Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
    Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A MLH1 polymorphism that increases cancer risk is associated with better outcome in sporadic colorectal cancer.
    Nejda N; Iglesias D; Moreno Azcoita M; Medina Arana V; González-Aguilera JJ; Fernández-Peralta AM
    Cancer Genet Cytogenet; 2009 Sep; 193(2):71-7. PubMed ID: 19665066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma.
    Patel SH; Kneuertz PJ; Delgado M; Kooby DA; Staley CA; El-Rayes BF; Kauh JS; Sarmiento JM; Hanish S; Cohen C; Farris AB; Maithel SK
    Ann Surg Oncol; 2011 Nov; 18(12):3384-90. PubMed ID: 21590454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.